Antibiotic resistance is a major public health burden increasingly resulting in fatal patient outcomes. During the past decades, multidrug-resistant organisms have become a global threat. As of today, antibiotic-resistant infections claim ~700,000 lives per year. The continued rise in resistance is projected to claim more than 10 million casualties per year by 2050 and a concomitant reduction of 2% to 3.5% in the gross domestic product.
ARES Technology combines the GEnetic Antibiotic Resistance and Susceptibility Database and Platform (GEAR), the most comprehensive collection of pathogen genomes and antibiotic resistance profiles, with proprietary data analysis workflows and interpretation applications into a comprehensive platform for Diagnostics, Pharma as well as Research & Epidemiology solutions. ARES Technology is the enabling platform for effective diagnostic and therapeutic solutions in the fight against antibiotic resistance.
Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley